Takahashi K, Minato K, Ikeno N, Watanabe M, Endo H, Yamamoto H
Am J Obstet Gynecol. 1983 May 1;146(1):74-9. doi: 10.1016/0002-9378(83)90930-4.
Serum methanol extracts were obtained from nine women with the galactorrhea-amenorrhea syndrome, 24 pregnant women in the third trimester, and 18 normal men and women. The serum extract released prolactin (PRL) in significant amounts from rat anterior pituitary in vitro. The extracts from patients with galactorrhea-amenorrhea released PRL in large quantities. A significant positive correlation was observed between the PRL-releasing activity and serum PRL levels in individual samples from the pregnant women and normal subjects but not from the patients with galactorrhea-amenorrhea. Bromocriptine therapy suppressed serum PRL levels of five patients without tumors but increased the PRL-releasing activity in three out of five patients after treatment for 1 or 2 months. Apparently hypothalamic regulation of PRL secretion was disrupted in these three patients after bromocriptine therapy.
从9名患有溢乳-闭经综合征的女性、24名孕晚期孕妇以及18名正常男性和女性中获取血清甲醇提取物。该血清提取物在体外能从大鼠垂体前叶中大量释放催乳素（PRL）。溢乳-闭经综合征患者的提取物能大量释放PRL。在孕妇和正常受试者的个体样本中，PRL释放活性与血清PRL水平之间存在显著正相关，但溢乳-闭经综合征患者的样本中未观察到这种相关性。溴隐亭治疗可使5名无肿瘤患者的血清PRL水平降低，但在治疗1或2个月后，5名患者中有3名患者的PRL释放活性增加。显然，溴隐亭治疗后，这3名患者下丘脑对PRL分泌的调节受到了干扰。
